Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi (lecanemab) for early Alzheimer’s disease (AD). The regulatory body has ...

Eisai and Biogen get another chance. Read why the latest from the two companies is a big step forward even though it's still just a glimmer of hope for Alzheimer’s sufferers.

Biogen, Eisai, and all other drug companies seeking FDA accelerated approval for a class of Alzheimer's drugs known as monoclonal antibodies would fall under Medicare's decision to pay for the ...

Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review. Hotspots ranked Start the day smarter ...

Nine months after the U.S. launch of Eisai Limited (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Leqembi, the first drug shown to slow Alzheimer’s progression, adoption faces hurdles due to ...

Biogen and Eisai also plan to submit the drug for full approval by the end of March. Advertisement Brian Skorney, an analyst at the investment bank Baird said the results of the lecanemab trial ...

Biogen and Eisai used the accelerated pathway to claim a controversial approval of their first amyloid-targeting drug Aduhelm (aducanumab), which has been a spectacular failure commercially.

Eisai and Biogen had planned to file their rolling BLA sooner using the existing fast-track designation for intravenous Leqembi but were rebuffed by the US regulator, ...

Once again, Eisai and Biogen are touting success for an anti-amyloid drug that has limited efficacy combined with safety issues.The first and most important point to make about lecanemab (formerly ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

Biogen’s partner, Japan-based Eisai, leads the clinical development and regulatory submissions for Leqembi. Though both companies co-commercialize and co-promote the drug, Eisai has the final ...